Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News United Therapeutics Corp UTHR

Healthcare Biotechnology
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended... see more

Recent & Breaking News (NDAQ:UTHR)

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

Business Wire November 5, 2024

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

Business Wire October 30, 2024

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service

Business Wire October 23, 2024

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024

Business Wire October 23, 2024

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting

Business Wire September 24, 2024

United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind-Ever

Business Wire September 10, 2024

United Therapeutics Corporation to Present at Upcoming Investor Conferences

Business Wire August 28, 2024

United Therapeutics Corporation Reports Second Quarter 2024 Financial Results

Business Wire July 31, 2024

United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024

Business Wire July 24, 2024

United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Business Wire July 10, 2024

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors

Business Wire June 27, 2024

United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire June 5, 2024

United Therapeutics Corporation Reports First Quarter 2024 Financial Results

Business Wire May 1, 2024

United Therapeutics Announces World's First Successful Xenothymokidney Transplant

Business Wire April 24, 2024

United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024

Business Wire April 24, 2024

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Business Wire April 16, 2024

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Business Wire March 26, 2024

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Business Wire March 25, 2024

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

Business Wire March 5, 2024

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

Business Wire February 27, 2024